References
- Arbus C, Benyamina A, Llorca PM, et al. (2007). Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci 32:357–66
- Chen R, Zhou Y, Tian J, et al. (2009). Determination of gliqudone in human plasma by HPLC-fluorescence and bioequivalence of 2 gliqudone tablets. Centr South Pharm 4:282–5
- Eagling VA, Tjia JF, Back DJ. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107–14
- Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678–85
- Faucette SR, Hawke RL, Shord SS, et al. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123–9
- Grzeszczak W, Strojek K. (1993). Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II. Pol Tyg Lek 48:38–9
- Holstein A, Hahn M, Patzer O, et al. (2011). Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 67:471–6
- Holstein A, Hammer C, Hahn M, et al. (2010). Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 9:675–81
- Holstein A, Plaschke A, Ptak M, et al. (2005). Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmcol 60:103–6
- Malaisse WJ. (2006). Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drug R D 7:331–7
- Ma XC, Ning J, Ge GB, et al. (2011). Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human. Drug Metab Dispos 39:675–82
- Narimatsu S, Yonemoto R, Saito K, et al. (2006). Oxidative metabolism of 5-methoxy-N, N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 71:1377–85
- Ramirez J, Innocenti F, Schuetz EG, et al. (2004). CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 32:930–6
- Tang C, Shou M, Mei Q, et al. (2000). Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453–9
- Tuerk TR, Bandur S, Nuernberger J, et al. (2008). Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin Nephrol 70:26–30
- Wang X, Yeung JH. (2010). Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. J Pharm Pharmacol 62:1077–83
- Yamazaki H. (2000). Roles of human cytochrome P450 enzymes involved in drug metabolism and toxicological studies. Yakugaku Zasshi 120:1347–57
- Yanardag R, Ozsoy-Sacan O, Orak H, Ozgey Y. (2005). Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Drug Chem Toxicol 28:483–47
- Youdim K, Dodia R. (2010). Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis--Menten constants. Xenobiotica 40:235–44